drugset / Trial / NCT00073411

Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression

NCT00073411

Phase 3 Completed 675 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purposes of this study are to determine: * The safety of duloxetine and any side effects that might be associated with it. * How duloxetine compares to escitalopram and placebo (an inactive ingredient)

Timeline

Start
2003-11
Primary completion
Completion
2005-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg
Subject Duloxetine Small molecule 120 mg
Subject Escitalopram Small molecule 10 mg
Subject Escitalopram Small molecule 20 mg

Indications